The Microfluidics team of experts was proud to exhibit at the 2024 Interphex tradeshow on April 16-18 at the Javits Center in New York City. This esteemed tradeshow is "the leading global pharmaceutical and biotechnology event that fuses industry innovation with expert-led conference. This dynamic platform unites professionals, fostering collaborations and providing a comprehensive view of advancements in pharmaceutical manufacturing, process development, and regulatory compliance ..read more

Dr. Yang Su, of the Microfluidics team, recently offered an insightful webinar focused on cosmetic manufacturing and methods of gaining competitive advantages through stable nanoemulsions, liposome formations, and other applications ..read more

Cells are the basic building blocks of all living things. From bacterial cells like E. Coli, to yeast cells like Pichia pastoris to algae cells and others, proteins play vital roles in scientific breakthroughs such as gene therapy and vaccine production. The key to recovering the intracellular content is through the important process of cell lysis. This is the process of breaking cell membranes to recover the intracellular content ..read more

Microfluidics International Corporation was proud to have Steve Mesite, Director Microfluidics Machines, selected to present at the ECCPM FORUM 2023. The European Consortium for Continuous Pharmaceutical Manufacturing FORUM was held September 13-14 in Graz, Austria and addressed Novel Approaches for Advanced Manufacturing ..read more

Dr. Yang Su, Manager of New Technology and Applications at Microfluidics International Corp., was pleased to be selected to present at RNA Therapeutics & Delivery U.S 2023 symposium ..read more

Microfluidics’ recent webinar entitled “Comparison of Biotest HSA and Recombinant HSA for the Preparation of Nano Albumin Bound (nab) Paclitaxel using Microfluidizer® Technology” was well engaged and received a great deal of interest ..read more

With all the setbacks and frustrations of the COVID-19 pandemic, one positive development was the production of several vaccines using mRNA (Messenger Ribonucleic Acid) technology ..read more

The Microfluidics team was excited to participate as joint presenters, with leaders from Biotest and Research Center Pharmaceutical Engineering (RCPE), on our recent webinar ..read more

Nanoparticle albumin bound (nab) technology is an important carrier for delivering low-aqueous solubility, high-toxicity therapeutic agents with fewer side effects than traditional systems, which makes it ideally suited for use in chemotherapy medication ..read more

After a three-year absence, Microfluidics International Corporation made a long-awaited return to the Show floor at AAPS PharmSci in Boston, MA (October 16 – 19 ..read more